Array ( [1610361492] => Array ( [wordfence_batchReportFailedAttempts] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => [args] => Array ( ) ) ) ) [1610361503] => Array ( [wordfence_batchReportBlockedAttempts] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => [args] => Array ( ) ) ) ) [1610361573] => Array ( [wp_privacy_delete_old_export_files] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1610361717] => Array ( [wordfence_processAttackData] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => [args] => Array ( ) ) ) ) [1610362081] => Array ( [wpm_update_stats] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1610363592] => Array ( [wordfence_hourly_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1610371926] => Array ( [wp_update_themes] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) [wp_update_plugins] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1610372674] => Array ( [wp_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610375353] => Array ( [wp_version_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1610378273] => Array ( [wp_session_garbage_collection] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1610381224] => Array ( [akismet_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610384211] => Array ( [yoast_tracking] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610401261] => Array ( [wpseo_permalink_structure_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) [wpseo_home_url_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610401274] => Array ( [wpseo-reindex] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610432685] => Array ( [recovery_mode_clean_expired_keys] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610435312] => Array ( [ai1wm_storage_cleanup] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610441371] => Array ( [wp_scheduled_auto_draft_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610446511] => Array ( [delete_expired_transients] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610446552] => Array ( [wpseo-reindex-links] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610447214] => Array ( [wordfence_daily_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1610459400] => Array ( [wordfence_start_scheduled_scan] => Array ( [8a5658e03958f7d8e19261706e1338c0] => Array ( [schedule] => [args] => Array ( [0] => 1610459400 ) ) ) ) [1610519090] => Array ( [wp_site_health_scheduled_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => weekly [args] => Array ( ) [interval] => 604800 ) ) ) [1610718600] => Array ( [wordfence_start_scheduled_scan] => Array ( [b53ad193bb4be13c7155cae313a1d749] => Array ( [schedule] => [args] => Array ( [0] => 1610718600 ) ) ) ) )
Etiquetas: 14 mayo 2007, 14/05/2007, 14/05/2008, 2005/2006, Abatacept, Agencia Europea de Medicamentos, Antibacterianos, Antidiabéticos, Antidiabéticos orales, Antitrombóticos, Autorizaciones de medicamentos, Citostáticos, Colesevelam, Darunavir, Decitabina, Deferasirox, EMEA, Entecavir, Estiripentol, Eszopiclona, Exenatida, Fanolesomab 99 Tc, FDA, Fluoroquinolonas, Food Drug Administration, Gemtuzumab ozogamicina, Grupo, Hormonas hipotalámicas e hipofisarias, Hormonas liberadores de gonadotropinas, Inmunoestimulantes, Inmunosupresores selectivos, Ivermectina, Laboratorio, Laxantes, Lenalidomida, Lubiprostona, Madrid, Medicamento, medicamentos, Micafungina, Natalizumab, Nepafenaco, Nuevos principios activos, PaM digital, Panitumumab, Panorama Actual del Medicamento, Parches de testosterona, Perflutren, Porfímero, Pramlintida, Principio activo, Rimonabant, Rufinamida, salud, Sanidad, Secretina, Sitaxentán, Telbivudina, Temoporfina, Terapia cardiaca, Ziconotida, Zileuton.